Skip to main content

Advertisement

Table 3 Costs, QALYs and ICER values for all analyzed populations

From: Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective

Incremental SC IV Oral
SEC ETN ETN BS ADA ADA BS CER P GOL UST INF APR
SEC 150 mg versus comparators in Biologic Naïve population without moderate to severe psoriasis)
Total cost (€) 187,776 208,375 186,581 207,568 186,543 204,899 197,566 214,749 230,650 192,319
QALYs 8.01 7.67 7.67 7.47 7.47 7.34 7.15 7.54 8.07 7.13
ICER (€/QALY) Dominates 3514 Dominates 2283 Dominates Dominates Dominates 680,427a Dominates
SEC 300 mg versus comparators in Naïve PsA with moderate to severe psoriasis population
Total cost (€) 231,477 214,225 192,431 213,555 192,530 210,480 203,855 220,313 235,354 198,422
QALYs 7.78 7.12 7.12 6.9 6.9 6.78 6.57 6.98 7.54 6.57
ICER (€/QALY) 25,872 49,365 20,342 37,251 20,955 22,819 13,941 Dominates 27,233
SEC 300 mg versus comparators in experienced population
Total cost (€) 256,019 € 215,772 194,424 210,940 191,975 211,230 201,556 217,194 231,440 196,293
QALYs 8.75 7.35 7.35 7.05 7.05 7.00 6.75 7.12 7.61 6.68
ICER (€/QALY) 28,742 40,546 26,609 34,959 25,623 27,293 23,832 21,631 28,939
  1. ADA, adalimumab; APR, apremilast; BS, biosimilar; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; IV, Intra Venous; PsARC, Psoriatic arthritis response criteria; QALY, quality-adjusted life-year; SEC 150, secukinumab 150 mg; SEC 300, secukinumab 300 mg; SC, subcutaneous; SoC, standard of care; UST, ustekinumab
  2. aThe ICER of Sec 150 mg vs. INF